Jean Paul Medina Carrion

Fondazione IRCCS Istituto Neurologico Carlo Besta
Country flagItaly

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (15)

Year:

2025

Year:

2025

Background and purpose Thalamic alterations have been reported as a major feature in presymptomatic and symptomatic patients carrying the C9orf72 mutation across the frontotemporal dementia–amyotrophic lateral sclerosis (ALS) spectrum. Specifically, the pulvinar, a high‐order thalamic nucleus and timekeeper for large‐scale cortical networks, has been hypothesized to be involved in C9orf72 ‐related neurodegenerative diseases. We investigated whether pulvinar volume can be useful for differential diagnosis in ALS C9orf72 mutation carriers and noncarriers and how underlying functional connectivity changes affect this region. Methods We studied 19 ALS C9orf72 mutation carriers ( ALSC9+ ) accurately matched with wild‐type ALS ( ALSC9 −) and ALS mimic ( ALSmimic ) patients using structural and resting‐state functional magnetic resonance imaging data. Pulvinar volume was computed using automatic segmentation. Seed‐to‐voxel functional connectivity analyses were performed using seeds from a pulvinar functional parcellation. Results Pulvinar structural integrity had high discriminative values for ALSC9+ patients compared to ALSmimic (area under the curve [AUC] = 0.86) and ALSC9 − (AUC = 0.77) patients, yielding a volume cutpoint of approximately 0.23%. Compared to ALSmimic , ALSC9 − showed increased anterior, inferior, and lateral pulvinar connections with bilateral occipital–temporal–parietal regions, whereas ALSC9+ showed no differences. ALSC9+ patients when compared to ALSC9 − patients showed reduced pulvinar–occipital connectivity for anterior and inferior pulvinar seeds. Conclusions Pulvinar volume could be a differential biomarker closely related to the C9orf72 mutation. A pulvinar–cortical circuit dysfunction might play a critical role in disease progression and development, in both the genetic phenotype and ALS wild‐type patients.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Collaborators (14)

Eleonora Dalla Bella

Fondazione IRCCS Istituto Neurologico Carlo Besta

ITALY
View details

Alberto Redolfi

Head of Laboratory

-

ITALY
View details

Mario Stanziano

Fondazione IRCCS Istituto Neurologico Carlo Besta

ITALY
View details

Sara Palermo

Associate Professor

University of Turin

ITALY
View details

Cristina Moglia

-

ITALY
View details

luca giani

Istituti Clinici Scientifici Maugeri SpA IRCCS Lumezzane

ITALY
View details

Davide Fedeli

Istituto Neurologico Carlo Besta

ITALY
View details

Nicola CANESSA

Associate professor M-PSI/02

Istituto Universitario di Studi Superiori IUSS

ITALY
View details

John‐Paul Taylor

-

UNITED KINGDOM
View details

francesco ghielmetti

Fondazione IRCCS Istituto Neurologico Carlo Besta

ITALY
View details

Federica Agosta

-

ITALY
View details

matilde leonardi

Fondazione IRCCS Istituto Neurologico Carlo Besta

ITALY
View details

GIOVANNI SAVINI

Humanitas University

ITALY
View details

monica consonni

Fondazione IRCCS Istituto Neurologico Carlo Besta

ITALY
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.